Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?. (22nd December 2015)

• Record Type: Journal Article
• Authors: Grard, Soazic; Catho, Gaud; Valour, Florent; Bouaziz, Anissa; Perpoint, Thomas; Braun, Evelyne; Biron, François; Miailhes, Patrick; Ferry, Tristan; Chidiac, Christian; Souquet, Pierre-Jean; Couraud, Sébastien; Lina, Gérard; Goutelle, Sylvain; Veziris, Nicolas; Dumitrescu, Oana; Ader, Florence; Ader, F.; Biron, F.; Boibieux, A.; Bouaziz, A.; Bouledrak, K.; Braun, E.; Catho, G.; Chidiac, C.; Chumbi-Flores, W.; Couraud, S.; Devouassoux, G.; Dumitrescu, O.; Ferry, T.; Freymond, N.; Gardes, S.; Gerbier-Colomban, S.; Gillet, Y.; Goutelle, S.; Grando, J.; Grima, R.; Hees, L.; Jubin, V.; Kiakouama-Maleka, L.; Lina, G.; Maury, J.M.; Miailhes, P.; Perpoint, T.; Perrot, Em.; Perrot, Emm; Reix, P.; Renaud-Baron, A.S.; Ronin, V.; Senechal, A.; Souquet, P.J.; Thai Van, H.; Tronc, F.; Valour, F.; Vanhems, P.;
• Is Part Of: Open forum infectious diseases. Volume 2:Number 4(2015)
• Publication Date: 2015-12-22
• Subjects: ethionamide -- linezolid -- multidrug-resistant tuberculosis -- neuropathy; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofv175
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Linezolid (LNZ), a group 5 antituberculous drug (unclear efficacy), was used in the starter regimens of 23 adults with multidrug-resistant tuberculosis. The LNZ-containing regimens were effective in achieving culture conversions and relapse-free outcomes. The most frequent LNZ-related side effect was neuropathy. We propose that LNZ should be reclassified among bactericidal second-line drugs.